Imkeldi

Generic name: imatinib

Used for: Chronic myeloid leukemia (Ph+ CML) · Acute lymphoblastic leukemia (Ph+ ALL) · Gastrointestinal stromal tumors (GIST) · Bone marrow disorders (MDS/MPD) with PDGFR gene changes · Aggressive systemic mastocytosis · Hypereosinophilic syndrome or chronic eosinophilic leukemia · Dermatofibrosarcoma protuberans (a skin cancer) · 6 more

How do you pay?

How to pay the least

Ask for the cash price

Imkeldi

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you.

  1. Ask your pharmacy for Imkeldi’s cash price, and one or two other pharmacies too.
  2. Imkeldi’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameImkeldi
Authorized genericimatinib
Regular genericimatinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Other forms onlyAsk your doctor
Same as Imkeldi?
The original
–
–

Brand nameThe maker’s card

IMKELDI Savings Program

Savings card from Shorla Oncology Inc

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $15 a month

The card takes up to $575 a month off your co-pay.

Sign up on imkeldi.com 

In the maker’s words

“If you have commercial drug insurance that covers IMKELDI, you can get a 30-day supply for as little as $15.”

From the maker’s offer on imkeldi.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Imkeldi itself, from the same company, sold without the brand name, and usually for less. For now Imkeldi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Imkeldi is a kinase inhibitor indicated for the treatment of:

  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
  • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.
  • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
  • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
  • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.
  • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.
  • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
  • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
  • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.

Source: the FDA label for Imkeldi (Shorla Oncology Inc.,), December 5, 2024. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/imkeldi/